Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2012 Jun 23;8(3):416-8.
doi: 10.1098/rsbl.2011.1203. Epub 2012 Jan 25.

Therapeutic antimicrobial peptides may compromise natural immunity

Michelle G J L Habets  1 , Michael A Brockhurst
Affiliations

Therapeutic antimicrobial peptides may compromise natural immunity

Michelle G J L Habets et al. Biol Lett. .

Abstract

Antimicrobial peptides (AMPs) have been proposed as a promising new class of antimicrobials despite warnings that therapeutic use could drive the evolution of pathogens resistant to our own immunity peptides. Using experimental evolution, we demonstrate that Staphylococcus aureus rapidly evolved resistance to pexiganan, a drug-candidate for diabetic leg ulcer infections. Evolved resistance was costly in terms of impaired growth rate, but costs-of-resistance were completely ameliorated by compensatory adaptation. Crucially, we show that, in some populations, experimentally evolved resistance to pexiganan provided S VSports手机版. aureus with cross-resistance to human-neutrophil-defensin-1, a key component of the innate immune response to infection. This unintended consequence of therapeutic use could drastically undermine our innate immune system's ability to control and clear microbial infections. Our results therefore highlight grave potential risks of AMP therapies, with implications for their development. .

PubMed Disclaimer

"V体育2025版" Figures

Figure 1.
Figure 1.
Evolved resistance to pexiganan has associated costs that can be ameliorated by compensatory adaptation. (a) VMAX plotted against pexiganan MIC for ancestral and evolved bacteria. Asterisks indicate significant difference by t-test between ancestral and evolved VMAX (**p ≤ 0.001, *** p ≤ 0.0001). (b) VMAX of ancestral and evolved SA3 bacteria before (light grey) and after (dark grey) selection in the absence of pexiganan. All compensated bacteria retained resistance to pexiganan (data not shown).
Figure 2.
Figure 2.
Resistance to pexiganan provides cross-resistance to HNP-1. Bars represent the ratio of growth rates in presence versus absence of HNP-1 for ancestral (light grey) and evolved (dark grey) bacteria; a value of 1 represents no inhibition of growth by HNP-1.
See this image and copyright information in PMC

References

    1. Hancock R. E. W., Sahl H. G. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551–155710.1038/nbt1267 (doi:10.1038/nbt1267) - DOI - DOI - PubMed
    1. Bell G., Gouyon P. H. 2003. Arming the enemy: the evolution of resistance to self-proteins. Microbiology 149, 1367–137510.1099/mic.0.26265-0 (V体育官网 - doi:10.1099/mic.0.26265-0) - DOI - DOI - PubMed
    1. Eckert R. 2011. Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol. 6, 635–65110.2217/FMB.11.27 (doi:10.2217/FMB.11.27) - DOI - DOI - PubMed
    1. Bell G., Perron G. G., Zasloff M. 2006. Experimental evolution of resistance to an antimicrobial peptide. Proc. R. Soc. B 273, 251–25610.1098/rspb.2005.3301 (doi:10.1098/rspb.2005.3301) - DOI - DOI - PMC - PubMed
    1. Ge Y. G., MacDonald D., Henry M. M., Halt H. I., Nelson K. A., Lipsky B. A., Zasloff M. A., Holroyd K. J. 1999. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn. Microbiol. Infect. Dis. 35, 45–5310.1016/S0732-8893(99)00056-5 (doi:10.1016/S0732-8893(99)00056-5) - DOI - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources